Argenx highlights vyvgart data at aan 2025 setting new standard in sustained efficacy and improved quality of life measures for patients living with gmg and cidp

Adapt-nxt data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized vyvgart dosing for gmg patients adhere+ oral presentation features long-term cidp data demonstrating vyvgart hytrulo's durable efficacy, sustained functional improvements and favorable safety profile argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of argx-119 (musk agonist) support pipeline-in-a-product development plan april 8, 2025, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of 15 abstracts, including an oral presentation, at the 2025 american academy of neurology (aan) annual meeting from april 5 – 9, 2025 in san diego, ca. the presentations showcase long-term data of vyvgart® (iv: efgartigimod alfa-fcab and sc or hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gmg) and chronic inflammatory demyelinating polyneuropathy (cidp) with a favorable safety profile.
ARGX Ratings Summary
ARGX Quant Ranking